This contract expires in 48 days (Oct 31, 2026).
MEMED DIAGNOSTICS LTD - MEMED DIAGNOSTICS- THE R&D EFFORT TO DEMONSTRATE CLINICAL UTILITY OF MEMED BV, RAPID HOST-BASED DIAGNOSTIC (HBD) FOR DISTINGUISHING BACTERIAL VS VIRAL INFECTION
Key Details
Description
MEMED DIAGNOSTICS- THE R&D EFFORT TO DEMONSTRATE CLINICAL UTILITY OF MEMED BV, RAPID HOST-BASED DIAGNOSTIC (HBD) FOR DISTINGUISHING BACTERIAL VS VIRAL INFECTION
Context & Analysis
On Oct 31, 2025, Department of Health and Human Services obligated $727,799.32 to MEMED DIAGNOSTICS LTD for memed diagnostics- the r&d effort to demonstrate clinical utility of memed bv, rapid host-based diagnostic (hbd) for distinguishing bacterial vs viral infection. The award is classified under NAICS 541714 — RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY) and issued as a firm fixed price contract. Competition extent: full and open competition with 99 offers received. The procurement used a NO SET ASIDE USED. set-aside. The contract is scheduled through Oct 31, 2026 — approximately 2 months remaining. This award is one of several similar procurements from Department of Health and Human Services under NAICS 541714 — related awards are listed below.
Contractor Information
Similar Awards
CLINICAL SERVICES NETWORK- CLINICAL TRIAL PLANNING AND EXECUTION
ALLUCENT GOVERNMENT SERVICES (US) LLC
$370.1M
CLINICAL SERVICES NETWORK- CLINICAL TRIAL PLANNING AND EXECUTION
ICON GOVERNMENT AND PUBLIC HEALTH SOLUTIONS, INC.
$330.2M
CLINICAL SERVICES NETWORK- CLINICAL TRIAL PLANNING AND EXECUTION
TECHNICAL RESOURCES INTERNATIONAL, INC.
$317.1M
ANTIBIOTIC FOR TREATMENT OF A BIOTHREAT INDICATION
PARATEK PHARMACEUTICALS, INC
$265.3M
ASPR-18-04963 -- FUNDING FOR BALOXAVIR MARBOXIL ACTIVITIES FOR BASE PERIOD TASK UNDER THE GENENTECH OTA
GENENTECH INC
$243.7M
Stay Updated
Get notified about new opportunities matching your interests.